15
Oct
In a significant change, the US Food and Drug Administration (FDA) is set to reevaluate its previous decision to ban compounded forms of a popular weight-loss drug developed by Eli Lilly. This move comes after much debate over the accessibility and regulation of compounded medications, which are customized to meet patients' specific needs when standard FDA-approved options are not suitable. Compounded medications provide a critical healthcare solution for patients who require specific formulations not available on the commercial market. The FDA initially limited these releases due to concerns about safety, quality control, and the need for oversight in the preparation…
